Tiny study tests Tumor-Injected drug plus immunotherapy for tough cancers
NCT ID NCT05383170
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a new drug called CyPep-1, injected directly into tumors, combined with the immunotherapy pembrolizumab (Keytruda) in 6 people with advanced head and neck cancer, melanoma, or triple-negative breast cancer. The main goal was to check safety and side effects, not to cure the disease. Because it was very small and early, we cannot draw strong conclusions about how well it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CyPep-1 (a drug injected into tumors) and pembrolizumab (an immunotherapy drug, also known as Keytruda)
What this could lead to
If it works, this combination could shrink tumors and help control advanced cancers that are hard to treat.
What could go wrong
This is a very early, tiny study (only 6 people) focused on safety, not effectiveness. The results may not apply to larger groups, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AP-HM - Hôpital de la Timone
Marseille, France
-
Azienda Ospedaliero Universitaria Senese
Siena, Italy
-
CHRU de Besançon
Besançon, France
-
CHU Lille
Lille, France
-
Centre Leon Berard
Lyon, France
-
City Of Hope
Duarte, California, 91010, United States
-
Clinica Universidad de Navarra Madrid
Madrid, Spain
-
Clinica Universidad de Navarra Pamplona
Pamplona, Spain
-
EMC
Rotterdam, Netherlands
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Hospital Universitario 12 de Octubre
Madrid, Spain
-
Hospital Universitario HM Sanchinarro
Madrid, Spain
-
Hospital Universitario Virgen Macarena
Seville, Spain
-
Houston Methodist
Houston, Texas, 77030, United States
-
Hôpital Saint Louis - AP-HP
Paris, France
-
Institut Bergonie
Bordeaux, France
-
Institut Paoli Calmettes
Marseille, France
-
Institute Gustave Roussy
Villejuif, France
-
Istituto Europeo di Oncologia
Milan, Italy
-
Maastricht UMC
Maastricht, Netherlands
-
NKI/AvL
Amsterdam, Netherlands
-
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas, 75246, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213-2582, United States
-
Vall d'Hebron (VHIO)
Barcelona, Spain